Taiwan After more than two decades in Silicon Valley, Dr Jeng Her returned to Taiwan with a bold ambition: to help transform its emerging biotech sector into a globally recognised force in antibody innovation. As Founder and CEO of AP Biosciences, he has positioned the company at the forefront of bispecific…
China EpimAb Biotherapeutics’ Chengbin Wu explains why the expansion of bispecifics into solid tumors and autoimmune diseases marks a major therapeutic turning point. He outlines how, through rational antibody engineering and unique molecule formats, EpimAb has differentiated itself with safer, more effective therapies than its competitors, as well as how the…
See our Cookie Privacy Policy Here
